ArticleCurrent pharmaceutical design2026
Ibrutinib Loaded Nanostructured Lipid Carriers for the Management of Chronic Lymphocytic Leukemia: Synchronizing
Article in Current pharmaceutical design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluation of Method "Whiteness" in the Stability Analysis of Dexamethasone and PVP-I Ophthalmic Suspensions: Synergizing LC-MS/MS, In Silico Toxicology, and AGREE/GAPI Metrics.Biomedical chromatography : BMC · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIbrutinib is a selective tyrosine kinase inhibitor used to treat chronic lymphocytic leukemia (CLL). However, it has low oral bioavailability (2.9%), which is attributed to low solubility (0.002 mg/mL) and a first-pass effect. Ibrutinib-loaded nanostructured lipid carriers (IBR-NLCs) were prepared and investigated in this study to overcome the solubility and presystemic metabolism issues. The goal of the current study was to formulate IBR-NLCs for enhanced bioavailability. IBR-NLCs were optimized using a 32 factorial design and evaluated using various in vitro and in vivo parameters.
methodsIBR interaction with solid lipid (Glyceryl monostearate) and liquid lipid (oleic acid) was studied using molecular docking. The hot-melt ultrasonication method was used to formulate IBR-NLCs, and a 32 factorial design was used for optimization. Particle size, PDI, zeta potential, entrapment efficiency, DSC, XRD, FTIR, SEM, and in vitro study were used to evaluate the NLCs. HepG2 cell lines were used to study the in vitro cytotoxicity of IBR-NLCs and IBR suspension. IBR-NLCs were administered to male Wistar rats in the presence and absence of cycloheximide (CXI) to compare pharmacokinetic parameters. RESULTS AND DISCUSSION: Molecular docking confirmed good interaction between IBR-GMS and IBR-oleic acid. The optimized IBR-NLCs exhibited particle sizes, PDI, zeta potentials, and %EE of 154.5 ± 0.7 nm, 0.2 ± 0.0, - 25.8 ± 1.1 mV, and 84.0 ± 1.2%, respectively. Differential Scanning Calorimetry (DSC) reveals the development of molecular dispersion of IBR in the melted lipid matrix, and X-Ray Diffraction (XRD) studies show a decline in the crystalline drug peaks in the formulation's diffractogram. SEM images showed uniformity distributed spherical-shaped particles. According to an in vitro investigation, IBR-NLCs exhibited a sustained release pattern of 98.0 ± 0.5% with a Korsmeyer-Peppas model mechanism (R
conclusionIBR-NLCs appear to be promising as a novel innovative nanocarrier for the management of CLL.
Indexed as
Identifiers
40873270What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.